DE NOVO ANTIBODY DESIGN

We develop the next generation of Antibody Therapeutics using Generative-AI

AT A GLANCE

Who we are

Silica Corpora is a Therapeutics Company aiming to provide the next generation of therapeutic Antibodies using Gen-AI.

Our platform MALI, powered by proprietary Foundation Models for De Novo Antibody Design is capable of finding meaningful antibody candidates using only amino acid sequences.

We believe each project is different, and that is why we aim to work closely with our partners to build a shared pipeline.

WHY TO CHOOSE US

Find out why Silica Corpora is your best ally for Antibody Discovery

More Precision,
Less Time.

Our platform MALI makes the Drug Discovery process extremely accurate, finding the right candidates in record time and reducing the number of Antibodies to be tested experimentally in the pre-clinical trial phase.

Check our Whitepaper

gettyimages-1133973940-2048x2048-removeb

We want to grow with you.

Aside other CRO models, Silica Corpora wants to establish long-lasting partnerships to co-develop tailored and meaningful solutions. While being able to use all our existing tools, we use your accumulated data to create your tailored models and improve the quality of your future drug candidates.

Partner with Us

Boost accuracy without altering the process

Our technology doesn’t disrupt existing in vitro workflows of our customers, thus, our methods can be easily plugged into established in vitro workflows with no need for new equipment, expertise, or personnel.

Try Our Blind Test

OUR UNIQUENESS

A holistic approach to reach the next generation of drug development.

Taking advantage of the progress in Generative-AI, we developed a protein-LLM that works only with AA sequences, making the characterization stage much more agile.

Using AI models trained on amino acid sequences we can generate more quality Antibodies from scratch, without using In Vitro nor In Vivo Methods.